At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
Ixazomib Citrate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
In Brief
A Phase 1 clinical trial evaluating Ixazomib Citrate and Pevonedistat for Recurrent Multiple Myeloma and Refractory Multiple Myeloma. Completed, enrolled 8 participants across 9 sites.
Detailed Summary
This phase Ib trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartFeb 2020
Primary CompletionSep 2022
Study CompletionJul 2023
TodayJul 2026
First PostedDec 10, 2018
Enrollment StartFeb 10, 2020
Primary CompletionSep 12, 2022
Study CompletionJul 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.6 years ago
Interventions
Ixazomib Citratedrug
Given PO
Pevonedistatdrug
Given IV